Download MendeleyBroad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope.
Schoofs, T., Barnes, C.O., Suh-Toma, N., Golijanin, J., Schommers, P., Gruell, H., West Jr., A.P., Bach, F., Lee, Y.E., Nogueira, L., Georgiev, I.S., Bailer, R.T., Czartoski, J., Mascola, J.R., Seaman, M.S., McElrath, M.J., Doria-Rose, N.A., Klein, F., Nussenzweig, M.C., Bjorkman, P.J.(2019) Immunity 50: 1513
- PubMed: 31126879
- DOI: https://doi.org/10.1016/j.immuni.2019.04.014
- Primary Citation of Related Structures:
6OKP, 6OKQ - PubMed Abstract:
Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are potential therapeutic agents. We identified SF12 and related bNAbs with up to 62% neutralization breadth from an HIV-infected donor. SF12 recognized a glycan-dominated epitope on Env's silent face and was potent against clade AE viruses, which are poorly covered by V3-glycan bNAbs. A 3.3Å cryo-EM structure of a SF12-Env trimer complex showed additional contacts to Env protein residues by SF12 compared with VRC-PG05, the only other known donor-derived silentface antibody, explaining SF12's increased neutralization breadth, potency, and resistance to Env mutation routes. Asymmetric binding of SF12 was associated with distinct N-glycan conformations across Env protomers, demonstrating intra-Env glycan heterogeneity. Administrating SF12 to HIV-1-infected humanized mice suppressed viremia and selected for viruses lacking the N448 gp120 glycan. Effective bNAbs can therefore be raised against HIV-1 Env's silent face, suggesting their potential for HIV-1 prevention, therapy, and vaccine development.
Organizational Affiliation:
Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA; Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50931 Cologne, Germany; German Center for Infection Research, partner site Bonn-Cologne, 50931 Cologne, Germany.
